Fundraising Fox

Auron Therapeutics

Newton, US · Founded 2018 · Delaware corporation · 2 known investors

aurontherapeutics.com ↗
Biotech

Founders & leadership

Auron Therapeutics was founded in 2018 by Katharine Yen and Kate Yen.

KY
Katharine YenCo-founder
KY
Kate YeninFounder, CEO
CG
Christopher GuiffreExecutive

Board

AL
Alon LazarusBoard director
AF
Anna FrenchBoard director
AC
Alexandra CantleyBoard director
ESEric Shiozaki
Eric ShiozakiinBoard directorPartner at Revelation Partners
PO
Pini OrbachBoard director
SM
Serge MesserlianBoard director
VR
Victoria RichonBoard director
BD
Briggs Duncan MorrisonBoard director

Investors · 2

DCVC (Data Collective)Palo Alto · $5M – $25M
Polaris PartnersreportedBoston · $500K – $5Mvia Alexandra Cantley · board

Reported raises · per SEC filings

Form D private placements

$88.9M disclosed across 5 rounds · 2018–2026

▶$7.1MraisedAug 2026 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Katharine YenExecutive Officer, Director
  • Alexandra CantleyDirector
  • Briggs Duncan MorrisonDirector
  • Anna FrenchDirector
  • Pini OrbachDirector
  • Serge MesserlianDirector
  • Victoria RichonDirector
Offering amount
$12M
Amount sold
$7.1M
First sale
Aug 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$27.3MraisedDec 2025 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Briggs Duncan MorrisonDirector
  • Pini OrbachDirector
  • Katharine YenExecutive Officer, Director
  • Alexandra CantleyDirector
  • Victoria RichonDirector
  • Anna FrenchDirector
  • Serge MesserlianDirector
Offering amount
$42.3M
Amount sold
$27.3M
First sale
Dec 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$38.4MraisedOct 2023 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Christopher GuiffreExecutive Officer
  • Alon LazarusDirector
  • Anna FrenchDirector
  • Katharine YenExecutive Officer, Director
  • Victoria RichonDirector
  • Briggs Duncan MorrisonDirector
  • Alexandra CantleyDirector
  • Eric ShiozakiDirector
Offering amount
$48.2M
Amount sold
$38.4M
First sale
Jul 2022
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15.4MraisedDec 2020 · 25 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Isaac CiechanoverDirector
  • Katharine YenExecutive Officer, Director
  • John Duncan HiggonsDirector
  • Alon LazarusDirector
  • Anna FrenchDirector
Offering amount
$15.4M
Amount sold
$15.4M
First sale
Dec 2020
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$660KraisedJul 2018 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Katharine YenExecutive Officer, Director
  • John Duncan HiggonsDirector
Offering amount
$1.5M
Amount sold
$660K
First sale
Jun 2018
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

Who founded Auron Therapeutics?
Auron Therapeutics was founded by Katharine Yen, Kate Yen in 2018.
Who are Auron Therapeutics's investors?
Auron Therapeutics's investors include DCVC (Data Collective), Polaris Partners.
How much funding has Auron Therapeutics raised?
Auron Therapeutics has disclosed $88.9M raised across 5 rounds.
Where is Auron Therapeutics headquartered?
Auron Therapeutics is headquartered in Newton, US.